Genmab's Rina-S meets primary endpoint in Phase 3 ovarian cancer trial

what happened

Danish biotech Genmab has announced positive topline results from its global Phase 3 RAINFOL-02 trial of rinatabart sesutecan, known as Rina-S. The investigational antibody-drug conjugate was tested in patients with platinum-resistant ovarian cancer, and according to TradingView and Reuters, the trial met its primary endpoint of progression-free survival compared with investigator's choice chemotherapy.

In the intent-to-treat population of 584 patients, the risk of disease progression or death fell by 71% (HR 0.29). In the primary analysis set of 492 patients, the reduction was 67% (HR 0.33). Overall survival, the key secondary endpoint, also improved significantly in both populations. The safety profile was consistent with what is already known, with no new safety signals identified. Genmab plans to discuss next steps with regulators worldwide and will host an investor update on October 28.

why it matters

This is the first Phase 3 readout for the Rina-S program, so investors will watch the regulatory path and the timing of any filing closely. The result strengthens the company's pipeline, but the lasting effect on the shares will depend on approval and commercial prospects for the drug.

market impact

Genmab and biotech sector: positive Phase 3 data raises expectations for the Rina-S drug candidate

tags

instruments